Bisphosphonates for osteoporosisReferences
Citations
-
American College of Obstetricians and Gynecologists
(2004, reaffirmed 2008). Clinical management guidelines for
obstetrician-gynecologists. Osteoporosis. ACOG Practice Bulletin No. 50.
Obstetrics and Gynecology, 103(1): 203–216.
-
Hochberg MC (2002). Bisphosphonates. In SR Cummings et
al., eds., Osteoporosis: An Evidence-Based Guide to Prevention and Management, pp. 181–195. Philadelphia: American College of
Physicians–American Society of Internal Medicine.
-
Bone JG, et al. (2004). Ten years' experience with
alendronate for osteoporosis in postmenopausal women. New England Journal of Medicine, 350(12): 1189–1199.
-
Woo S-B, et al. (2006). Systematic review: Bisphosphonates and osteonecrosis of the jaw. Annals of Internal Medicine, 144(10): 753–761.
-
Cosman F, et al. (2002). Selection of medications and
guidelines for fracture prevention. In SR Cummings et al., eds.,
Osteoporosis: An Evidence-Based Guide to Prevention and Management, pp. 273–281. Philadelphia: American College of
Physicians–American Society of Internal Medicine.
-
Black DM, et al. (2003). The effects of parathyroid
hormone and alendronate alone or in combination in postmenopausal osteoporosis.
New England Journal of Medicine, 349(13):
1207–1215.
-
Black DM, et al. (2005). One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. New England Journal of Medicine, 353(6): 555–565.
| |